# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k162840   
B. Purpose for Submission: New Device   
C. Measurand: Total 25-hydroxyvitamin D (25-OH vitamin D)   
D. Type of Test: Quantitative electrochemiluminescence immunoassay   
E. Applicant: Roche Diagnostics   
F. Proprietary and Established Names: Elecsys Vitamin D total II Vitamin D total II CalSet PreciControl Vitamin D total II Vitamin D CalCheck

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1825, Vitamin D Test System 21 CFR 862.1150, Calibrator 21 CFR 862.1660, Quality Control Material (assayed and unassayed)

2. Classification:

Class II   
Class II   
Class I, reserved

3. Product code: MRG – Vitamin D Test System JIT – Calibrator, secondary JJX – Quality Control Material

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use:

Elecsys Vitamin D total II

The Elecsys Vitamin D total II assay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma. This assay is to be used as an aid in the assessment of vitamin D sufficiency in adults. The electrochemiluminescence binding assay is intended for use on the cobas e 411 immunoassay analyzer.

CalSet Vitamin D total II

CalSet Vitamin D total II is used for calibrating the quantitative Elecsys Vitamin D total II assay on the cobas e 411 immunoassay analyzer.

# PreciControl Vitamin D total II

PreciControl Vitamin D total II is used for quality control of Elecsys Vitamin D total II assay on cobas e 411 immunoassay analyzer.

# CalCheck Vitamin D total II

This CalCheck set is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys Vitamin D total II reagent on the cobas e 411 immunoassay analyzer.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Roche Cobas e 411 analyzer

# I. Device Description:

1. The Elecsys Vitamin D total II reagent working solutions include:

PT1 Pretreatment reagent 1 (white cap), 1 bottle, $4 \mathrm { m L }$ : Dithiothreitol $1 \ \mathrm { g / L }$ , $\mathsf { p H } 5 . 5$ . PT2 Pretreatment reagent 2 (gray cap), 1 bottle, $4 \mathrm { m L }$ : Sodium hydroxide $2 8 ~ \mathrm { g / L }$ . M Streptavidin-coated microparticles (transparent cap), 1 bottle, $6 . 5 \mathrm { m L }$ :   
Streptavidin-coated microparticles $0 . 7 2 ~ \mathrm { m g / m L }$ ; preservative.   
R1 Vitamin D binding protein‑ $\operatorname { R u } / ( \log { y } )$ (gray cap), 1 bottle, $6 . 5 \mathrm { m L }$ :   
Ruthenium labeled vitamin D binding protein $1 0 0 ~ { \mu \mathrm { g / L } }$ ; bis‑tris propane buffer 100 mmol/L; albumin (human) $4 0 ~ \mathrm { g / L }$ ; $\mathrm { p H } 6 . 4$ ; preservative.   
R2 25‑hydroxyvitamin D\~biotin (black cap), 1 bottle, $6 . 5 \mathrm { m L }$ : Biotinylated 25‑hydroxyvitamin D $1 4 0 ~ { \mu \mathrm { g / L } }$ ; bis‑tris propane buffer $1 0 0 \mathrm { m m o l / L }$ ; $\mathrm { p H } 8 . 6$ ; preservative.

2. Calibrator:

CalSet Vitamin D total $\mathrm { I I }$ is a two concentration level set of lyophilized human serum . The CalSet includes Cal 1 (approximately $2 \mathrm { n g / m L }$ 25-hydroxyvitamin $\mathrm { D } _ { 3 }$ ) and Cal 2 (approximately $4 5 ~ \mathrm { n g / m L }$ 25-hydroxyvitamin $\mathrm { D } _ { 3 }$ ).

3. Control:

PreciControl Vitamin D total II materials are lyophilized human sera in two concentration ranges. Controls 1 and 2 (CTL 1 & CTL 2) are available in $1 . 0 \mathrm { m L }$ bottles with two defined concentrations of total 25-hydroxy vitamin D The target concentrations are approximately $1 3 ~ \mathrm { n g / m L }$ and $3 0 ~ \mathrm { n g / m L }$ .

4. Calibration Verification Materials:

Each set of CalCheck Vitamin D total II contains 5 lyophilized serum levels $( 1 . 0 \mathrm { m L } )$ . - Check 1: Approximate target range of $\leq 2 \mathrm { n g / m L }$

- Check 2: Approximate target range of $1 7 . 5 - 2 2 . 4 \ : \mathrm { n g / m L }$ - Check 3: Approximate target range of $4 6 . 5 - 5 4 . 4 \ : \mathrm { n g / m L }$ - Check 4: Approximate target range of $7 5 . 5 - 8 4 . 4 \mathrm { n g / m L }$ - Check 5: Approximate target range of $9 4 . 5 \mathrm { ~ -- } > 1 0 0 ~ \mathrm { n g / m L }$

The labeling for above materials that contain human blood or serum matrices include the following statement:

All human material should be considered potentially infectious. All products derived from human blood are prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Elecsys Vitamin D Assay

2. Predicate 510(k) number(s): k113546

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities and Differences for Assay</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceElecsys Vitamin D total IIk162840</td><td colspan="1" rowspan="1">Predicate deviceElecsys Vitamin D Assayk113546</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">This assay is intended forthe quantitativedetermination of total 25-hydroxyvitamin D in humanserum and plasma. Thisassay is to be used as an aidin the assessment of vitaminD sufficiency in adults.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Competition principlebinding protein</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection Method</td><td colspan="1" rowspan="1">Electrochemiluminescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Applications/Test Time</td><td colspan="1" rowspan="1">27 minutes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Method</td><td colspan="1" rowspan="1">2-point calibration based onmaster curve for specificreagent lot</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">LoB, LoD, LoQ</td><td colspan="1" rowspan="1">2 ng/mL, 3 ng/mL, 5 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument Platform</td><td colspan="1" rowspan="1">cobas e 411</td><td colspan="1" rowspan="1">Elecsys 2010, MODULAR</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ANALYTICS E170, cobase 411, cobas e 601, andcobas e 602</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and Li-heparin, K2-EDTA, K3-EDTA, PlasmaGel Seperation tubes (Li-Heparin)</td><td colspan="1" rowspan="1">Serum and Li-heparin, K2-EDTA, K3-EDTA, PlasmaGel Seperation tubes (Li-Heparin)</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">ID-LC-MS/MS traceable toNIST RMP 2972</td><td colspan="1" rowspan="1">LC-MS/MS</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">5 - 100.0 ng/mL</td><td colspan="1" rowspan="1">5 - 60.0 ng/mL</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities and Differences for Calibrator</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceCalSet Vitamin D total IIk162840</td><td colspan="1" rowspan="1">Predicate deviceVitamin D CalSetk113546</td></tr><tr><td colspan="1" rowspan="1">Intended Use/</td><td colspan="1" rowspan="1">CalSet Vitamin D total II isused for calibrating thequantitative ElecsysVitamin D total II</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">25-hydroxyvitamin D3</td><td colspan="1" rowspan="1">25-hydroxyvitamin D</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum matrix withadded 25-hydroxyvitaminD3</td><td colspan="1" rowspan="1">Human serum matrix withadded 25-hydroxyvitamin D</td></tr><tr><td colspan="1" rowspan="1">Target Ranges</td><td colspan="1" rowspan="1">Cal 1: approximately 2ng/mLCal 2: approximately 45ng/mL</td><td colspan="1" rowspan="1">Cal 1: approximately 2ng/mLCal 2: approximately 37ng/mL</td></tr><tr><td colspan="1" rowspan="1">Storage and Stability</td><td colspan="1" rowspan="1">Reconstituted calibrators:. At 2-8°C - 72 hours. At -20°C - 12 weeks(freeze only once). On the cobas e 411analyzer  up to 6 hours</td><td colspan="1" rowspan="1">Reconstituted calibrators:· At 2-8°C - 120 hours· At -20°C - 90 days (freezeonly once). On the cobas e 411analyzer  up to 5 hours</td></tr><tr><td colspan="1" rowspan="1">Calibration Interval</td><td colspan="1" rowspan="1">Calibration must beperformed once per reagentlot using fresh reagent (&lt; 24hours since registered).Renewed calibration:. After 3 months (12 weeks)using the same reagent lot. After 7 days (when using</td><td colspan="1" rowspan="1">Calibration must beperformed once per reagentlot using fresh reagent (&lt; 24hours since registered).Renewed calibration:· After 1 month (28 days)using the same reagent lot. After 7 days (when using</td></tr><tr><td>Item</td><td>Candidate Device CalSet Vitamin D total II k162840</td><td>Predicate device Vitamin D CalSet k113546</td></tr><tr><td></td><td>the same reagent kit on the analyzer) . As required e.g. quality control findings outside the defined limits</td><td>the same reagent kit on the analyzer) · As required e.g. quality control findings</td></tr><tr><td>Format</td><td>Lyophilized</td><td>outside the defined limits Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities and Differences for Control</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DevicePreciControl Vitamin Dtotal IIk162840</td><td colspan="1" rowspan="1">Predicate devicePreciControl Variak113546</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">PreciControl Vitamin Dtotal II is used for qualitycontrol of the ElecsysVitamin D total II assay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">25-hydroxyvitamin D</td><td colspan="1" rowspan="1">Vitamin B12, Ferritin, Folateβ-CTx, Osteocalcin,Parathyroid hormone25-hydroxyvitamin D,Calcitonin</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum matrix</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">25-hydroxy Vitamin DTarget Value</td><td colspan="1" rowspan="1">Target range:Level 1: Approx. 13 ng/mLLevel 2: Approx. 30 ng/mL</td><td colspan="1" rowspan="1">Target range:Level 0: Approx. 12.8 ng/mLLevel 1: Approx. 17 ng/mLLevel 2: Approx. 32 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Storage and Stability</td><td colspan="1" rowspan="1">Reconstituted controlserum:· At -20°C - 31 days (freezeonly once)· At 2-8°C - 72 hours· At 20-25°C - up to 5 hours</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Lyophilized</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Similarities and Differences for CalCheck</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceCalCheck Vitamin D total IIk162840</td><td colspan="1" rowspan="1">Predicate deviceElecsys Vitamin DCalCheck 5k113546</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">CalCheck Vitamin D total IIis an assayed control for usein calibration verificationand for use in theverification of the assayrange</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Target Ranges</td><td colspan="1" rowspan="1">Approximate targetconcentrations:· ≤ 5 ng/mL· 17.5 - 22.4 ng/mL· 46.5 - 54.4 ng/mL· 75.5 - 84.4 ng/mL. 94.5 -&gt;100 ng/mL</td><td colspan="1" rowspan="1">Approximate targetconcentrations:· ≤ 5.00 ng/mL· 10.5 - 19.5 ng/mL· 21.0 - 39.0 ng/mL· 33.6 - &gt; 60.0 ng/mL· 42.0 - &gt; 60.0 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">25-hydroxyvitamin D3</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage and Stability</td><td colspan="1" rowspan="1">Reconstituted controlserum:5 hours at 20-25°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Lyophilized</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A3: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline – Third Edition

CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition

CLSI C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition

# L. Test Principle:

The Elecsys Vitamin D total II assay employs a competitive protein binding assay which uses Vitamin D Binding Protein for detection of 25-OH Vitamin D. The sample is treated with pretreatment reagent in the first incubation period. This releases vitamin D from the endogenous vitamin D binding protein present in the patient’s sample. In the next incubation, vitamin D binding protein labeled with ruthenium is added and a complex is formed between the 25-OH Vitamin D and the ruthenylated vitamin D binding protein. In the 3rd and final incubation, streptavidin-coated microparticles are added along with 25-OH Vitamin D labeled with biotin. Any unbound ruthenium labeled vitamin D binding proteins become occupied with biotin-labeled vitamin D (25-OH). The complex consisting of the ruthenylated vitamin D binding protein and the biotinylated vitamin D (25-OH) becomes bound to the solid phase via interaction of the biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the electrochemiluminescence emission is detected. Results are determined using a calibration curve that is generated on each instrument by a 2 point calibration provided with the reagent bar code.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision was evaluated on a single cobas e 411 analyzer according to CLSI guideline EP5-A3 using one reagent lot for evaluation. The protocol consisted of testing 2 replicates of two levels of control, PreciControl Vitamin D total II, and five human serum samples per run, 2 runs per day for 21 days $\scriptstyle ( \ n = 8 4 )$ ). The samples were run in randomized order on the cobas e 411 analyzer. Serum samples used were all single donors (native as well as spiked).

Precision Results Summary:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within Run Precision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Human Serum 1</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>0.725</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.965</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>Human Serum 2</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>0.849</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>Human Serum 3</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>0.774</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>Human Serum 4</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>47.5</td><td rowspan=1 colspan=1>0.749</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Human Serum 5</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>92.6</td><td rowspan=1 colspan=1>1.76</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.40</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>PC Control 1</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>0.748</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>PC Control 2</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>29.1</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.56</td><td rowspan=1 colspan=1>5.4</td></tr></table>

# b. Linearity/assay reportable range:

The linearity study on the Elecsys Vitamin D total II was performed according to CLSI guideline EP06-A. A linearity sample set was prepared by diluting a high 25- OH vitamin D concentration serum and K3-EDTA plasma sample (single donors, spiked) with a depleted serum/plasma sample with a low 25-OH vitamin D concentration to obtain 11 concentrations throughout the measuring range. Samples were assayed in triplicate within a single run and analyzed by linear regression.

The linearity test results are summarized below:

Serum linearity results:

<table><tr><td rowspan=1 colspan=1>Mean observedconcentration(ng/mL)</td><td rowspan=1 colspan=1>Expectedconcentration(ng/mL)</td><td rowspan=1 colspan=1>AbsoluteDifference</td><td rowspan=1 colspan=1>% Difference</td></tr><tr><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>14.5</td></tr><tr><td rowspan=1 colspan=1>6.13</td><td rowspan=1 colspan=1>6.16</td><td rowspan=1 colspan=1>-0.671</td><td rowspan=1 colspan=1>-10.0</td></tr><tr><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>-0.954</td><td rowspan=1 colspan=1>-7.2</td></tr><tr><td rowspan=1 colspan=1>26.6</td><td rowspan=1 colspan=1>24.5</td><td rowspan=1 colspan=1>-0.622</td><td rowspan=1 colspan=1>-2.3</td></tr><tr><td rowspan=1 colspan=1>40.3</td><td rowspan=1 colspan=1>36.6</td><td rowspan=1 colspan=1>0.454</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>55.2</td><td rowspan=1 colspan=1>48.8</td><td rowspan=1 colspan=1>1.77</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>68.5</td><td rowspan=1 colspan=1>61.0</td><td rowspan=1 colspan=1>2.80</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>82.8</td><td rowspan=1 colspan=1>73.2</td><td rowspan=1 colspan=1>3.01</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>94.2</td><td rowspan=1 colspan=1>85.4</td><td rowspan=1 colspan=1>1.89</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>97.6</td><td rowspan=1 colspan=1>-1.10</td><td rowspan=1 colspan=1>-1.0</td></tr><tr><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>-6.58</td><td rowspan=1 colspan=1>-5.5</td></tr></table>

The linearity study has the following linear regression for serum samples:

$$
\mathbf { y } = 1 . 0 8 5 \mathrm { x } - 0 . 0 0 5 , \mathrm { R } ^ { 2 } = 0 . 9 8 8 0
$$

K3 EDTA plasma linearity results:

<table><tr><td rowspan=1 colspan=1>Mean observedconcentration(ng/mL)</td><td rowspan=1 colspan=1>Expectedconcentration(ng/mL</td><td rowspan=1 colspan=1>AbsoluteDifference</td><td rowspan=1 colspan=1>% Difference</td></tr><tr><td rowspan=1 colspan=1>0.814</td><td rowspan=1 colspan=1>0.814</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>6.09</td><td rowspan=1 colspan=1>6.27</td><td rowspan=1 colspan=1>-0.433</td><td rowspan=1 colspan=1>-6.5</td></tr><tr><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>-0.571</td><td rowspan=1 colspan=1>-4.6</td></tr><tr><td rowspan=1 colspan=1>24.5</td><td rowspan=1 colspan=1>22.7</td><td rowspan=1 colspan=1>-0.142</td><td rowspan=1 colspan=1>-0.6</td></tr><tr><td rowspan=1 colspan=1>37.6</td><td rowspan=1 colspan=1>33.6</td><td rowspan=1 colspan=1>0.884</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>50.7</td><td rowspan=1 colspan=1>44.5</td><td rowspan=1 colspan=1>2.10</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>55.4</td><td rowspan=1 colspan=1>3.11</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>74.6</td><td rowspan=1 colspan=1>66.3</td><td rowspan=1 colspan=1>3.51</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>85.5</td><td rowspan=1 colspan=1>77.2</td><td rowspan=1 colspan=1>2.89</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>95.1</td><td rowspan=1 colspan=1>88.2</td><td rowspan=1 colspan=1>0.829</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>-6.304</td><td rowspan=1 colspan=1>-2.9</td></tr><tr><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>-9.14</td><td rowspan=1 colspan=1>-7.7</td></tr></table>

Parameter of the linear regression for plasma samples:

$$
\operatorname { y } = 1 . 0 7 8 \mathrm { x } - 0 . 0 1 1 , \mathrm { R } ^ { 2 } = 0 . 9 9 7 1
$$

The linearity study results support the claimed measuring range of $5 . 0 - 1 0 0 ~ \mathrm { n g / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Standardization and Traceability

This method is in the process of being standardized in accordance with the Vitamin D Standardization Program (VDSP). The VDSP is an international collaborative effort to standardize the laboratory measurement of serum 25-OH vitamin D. This   
collaboration involves the coordinated efforts of the National Institutes of Health, Office of Dietary Supplements (ODS), the Centers for Disease Control and   
Prevention (CDC), the National Institutes for Standards and Technology (NIST), Ghent University, and other institutions. Please refer to   
http://ods.od.nih.gov/Research/VitaminD.aspx for more information on the VDSP program.

# CalSet value assignment:

The CalSet Vitamin D total II assigned values are determined with the Elecsys Vitamin D total II assay. The CalSet Vitamin D total II is traceable to the ID-LCMS/MS 25- hydroxyvitamin D Reference Measurement Procedure. The ID-LCMS/MS is traceable to the National Institute of Standards and Technology Standard Reference Material 2972. A native human serum sample panel (single donors) with RMP-assigned target values ${ \mathrm { R M P } } = { \mathrm { R } }$ eference Measurement Procedure: ID-LCMS/MS of the University of Ghent) is used for Reference Standardization to assign values to the Master Calibrators (sample curve consisting of human serum samples from single donors covering the entire measuring range).

For each CalSet Vitamin D total II manufactured, the calibrators are run in duplicate on at least three (3) cobas e 411 analyzers and at least two (2) MODULAR ANALYTICS E170/cobas e 601/cobas e 602 analyzers with all Vitamin D total II reagent lots available. The assigned value of each calibrator is defined as the median value obtained over at least six (6) runs on at least three (3) analyzers of the respective calibrator.The assigned values for CalSet Vitamin D total II are read from the master calibration curve. The values must fall within specified acceptable ranges for each lot.

# Control value assignment:

The PreciControl Vitamin D total II assigned values are determined with the Elecsys Vitamin D total II assay. The assigned values for PreciControl Vitamin D total II are read from the master calibration curve. Values are assigned for each lot of PreciControl Vitamin D total II in combination with each assay reagent lot available. The controls are run in duplicate on the MODULAR ANALYTICS E170 /cobas e 601/cobas e602 Analyzers. The assigned values obtained on the additional analyzer (cobas e 411) are compared to those obtained on the master analyzer platform (cobas e 601). The assigned value of each control level is defined as the median value obtained over at least six (6) determinations of the respective control level.

CalCheck value assignment:

For each CalCheck Vitamin D total II lot manufactured, the CalChecks are run in duplicate on at least two cobas analyzers with at least two runs. The assigned value of each CalCheck is defined as the median value obtained over at least six (6) determinations (runs) of the respective CalCheck and are read from the master calibration curve.

# Stability:

The calibrator, CalCheck, and control shelf-life and open-vial stability testing protocols and acceptance criteria were reviewed and found to be acceptable as summary tables below:

<table><tr><td rowspan=1 colspan=1>CalSet Vitamin D total II</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Shelf life (lyophilized) at 2-8°C</td><td rowspan=1 colspan=1>15 months</td></tr><tr><td rowspan=1 colspan=1>Open vial (reconstituted) at -20°C</td><td rowspan=1 colspan=1>12 weeks (freeze only once)</td></tr><tr><td rowspan=1 colspan=1>Open vial (reconstituted) 2-8°C</td><td rowspan=1 colspan=1>72 hours</td></tr><tr><td rowspan=1 colspan=1>On board stability on cobas e 411 analyzerat 20-25°</td><td rowspan=1 colspan=1>Up to 5 hours</td></tr><tr><td rowspan=1 colspan=1>On board stability on E170, cobas e 601,cobas e 602 analyzer at 20-25°C</td><td rowspan=1 colspan=1>Use only once</td></tr></table>

<table><tr><td rowspan=1 colspan=1>PreciControl Vitamin D total II</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Shelf life (lyophilized) at 2-8°C</td><td rowspan=1 colspan=1>15 months</td></tr><tr><td rowspan=1 colspan=1>Open vial (reconstituted) at -20°C</td><td rowspan=1 colspan=1>31 days (freeze only once)</td></tr><tr><td rowspan=1 colspan=1>Open vial (reconstituted) at 2-8°C</td><td rowspan=1 colspan=1>72 hours</td></tr><tr><td rowspan=1 colspan=1>On the analyzers at 20-25°C</td><td rowspan=1 colspan=1>Up to 5 hours</td></tr></table>

<table><tr><td rowspan=1 colspan=1>CalCheck Vitamin D total II</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Shelf life (lyophilized) at 2-8°C</td><td rowspan=1 colspan=1>18 months</td></tr><tr><td rowspan=1 colspan=1>Open vial (econstituted) at 20-25°C</td><td rowspan=1 colspan=1>4 hours</td></tr></table>

# d. Detection limit:

The Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantification (LoQ) studies were performed according to CLSI EP-17A2.

# Limit of Blank

To establish the Limit of Blank (LoB), one 25-hydroxyvitamin D depleted human serum sample pool was assayed in 10 replicates per run, 2 runs per day over 3 or more days with three reagent lots on one cobas e 411 analyzer for 60 total measurements. The Limit of Blank was determined as the $\mathsf { \bar { g } } \mathsf { \bar { s } } ^ { \mathrm { t h } }$ percentile of measurements of blank samples.

Based on this study, the sponsor defined the Limit of Blank as $2 \mathrm { n g / m L }$ .

# Limit of Detection

To determine the Limit of Detection (LoD), 5 low level diluted serum pools were measured using 3 reagents lots over 3 days, 2 runs per day, on one cobas e 411 analyzer with two replicates per sample per run for total measurements of 36. LoD was calculated according to as the following equation: $\mathrm { L o D } = \mathrm { L o B } + 1 . 6 5 3 ~ \mathrm { x }$ SD total (of low analyte samples).

Based on this study, the sponsor defined the Limit of Detection as $3 ~ \mathrm { n g / m L }$ .

# Limit of Quantitation

To determine the Limit of Quantitation (LoQ), intermediate precision was used to calculate the LoQ for serum as well as Li-Heparin, K2-EDTA, K3-EDTA plasma samples. Below are the studies for Serum and Plasma samples:

Serum: A minimum of 6 low level samples were prepared (native human serum samples as well as diluted) with concentrations around the expected LoQ. Each sample was evaluated in five replicates per run, three reagent lots, one run per day over five days $n { = } 2 5$ per sample).

Li-Heparin: 5 samples were evaluated in five replicates per run, one lot, one run per day over five days $n { = } 2 5$ per sample).

K2 and K3-EDTA: 7 samples were evaluated in five replicates per run, one lot, one run per day over five days $\mathrm { \Delta } \mathrm { n } { = } 3 5$ per sample).

The LoQ was defined as the lowest concentration with an inter-assay precision of $\leq 2 0 \%$ CV. Based on this study, the sponsor defined the Limit of Quantitation as $5 \mathrm { n g / m L }$ .

Detection limits results:

<table><tr><td rowspan=1 colspan=1>Limit of Blank</td><td rowspan=1 colspan=1>Limit of Detection</td><td rowspan=1 colspan=1>Limit of Quantitation</td></tr><tr><td rowspan=1 colspan=1>2 ng/mL</td><td rowspan=1 colspan=1>3 ng/mL</td><td rowspan=1 colspan=1>5 ng/mL</td></tr></table>

e. Analytical specificity:

Endogenous Interferences:

Potential interference from endogenous substances was evaluated. For each interfering substance, 3 serum samples containing low $\mathrm { { ( 1 0 \ n g / m L ) } }$ , mid $( 3 0 ~ \mathrm { n g / m L } )$ , and high $( 7 0 \mathrm { n g / m L } )$ concentrations of 25-hydroxyvitamin D were tested. An aliquot of each serum sample was spiked with the interfering substances. Another aliquot without any additives was used as the dilution pool. The interfering pool was diluted into the dilution pool in $10 \%$ increments. For bilirubin, $90 \%$ bilirubin and $10 \%$ ditaurobilirubin was used to mimic the natural ratio of both forms in human blood. The recovery for each sample was calculated by comparison to the reference sample. The sponsor considered significant interference as:

$\leq 2 0 ~ \mathrm { n g / m L }$ 25-hydroxyvitamin D: $: > 2 . 0 \ \mathrm { n g / m L }$ deviation from the unspiked reference value

$> 2 0 ~ \mathrm { n g / m L }$ 25-hydroxyvitamin D: $> 1 0 \%$ deviation from the unspiked reference value

The highest concentrations at which no significant interference was observed are shown below:

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest concentration of substance tested thatdemonstrated no significant interference</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>66 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>300 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>300 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholestrol</td><td rowspan=1 colspan=1>300 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>30 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>9 g/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid facror(RF)</td><td rowspan=1 colspan=1>1200 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin (IgG)</td><td rowspan=1 colspan=1>7g/dL</td></tr><tr><td rowspan=1 colspan=1>Serum Albumin</td><td rowspan=1 colspan=1>7g/dL</td></tr></table>

The labeling contains the following limitation:

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. $> 5 \mathrm { m g / d a y ) }$ until at least 8 hours following the last biotin administration. Patients taking $> 2 0 ~ \mathrm { m g }$ biotin per day may need to discontinue biotin intake for longer than 8 hours prior to testing with this assay.

# Human Anti-Mouse Antibodies (HAMA):

The effect of the presence of human anti-mouse antibodies on the Elecsys Vitamin D total II assay was assessed on the cobas e 411 immunoassay analyzer. Serum containing $8 0 5 ~ \mathrm { { n g / m L } }$ human anti-mouse antibody (HAMA) and control serum without interferent were measured in duplicate. The sponsor considered recovery of the HAMA-containing serum compared to the control serum of $1 0 0 \pm 1 0 \%$ to be significant interference.

The study results support the sponsor’s claim that HAMA up to $8 0 5 ~ \mathrm { { n g / m L } }$ does not significantly interfere with the Elecsys Vitamin D total II assay.

The effect on quantitation of 25-hydroxyvitamin D using the Elecsys Vitamin D total II assay in the presence of drugs was determined by comparing values obtained from samples spiked with 19 pharmaceutical compounds with the reference sample (unspiked). Two human serum samples (single donors, native as well as spiked) with 25-hydroxyvitamin D concentrations of approximately 30 and $7 0 ~ \mathrm { n g / m L }$ were used in the study. The two serum samples were divided into aliquots and spiked with the potential interferents. The reference sample without interferent was spiked with the respective amount of solvent only. The samples were measured on the cobas e 411 immunoassay analyzer. The sponsor defined significant interference as greater or equal to $\pm 1 0 \%$ of the reference value (unspiked sample).

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Highest concentration of spiked drugthat demonstrated no significantinterference (mg/L)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200</td></tr><tr><td rowspan=1 colspan=1>Acetylcystein</td><td rowspan=1 colspan=1>1660</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Na</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>2500</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Methyldopa +1.5</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>400</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Theophyllin</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>EinsAlpha (alfacalcidol)</td><td rowspan=1 colspan=1>0.003</td></tr><tr><td rowspan=1 colspan=1>ZEMPLAR (paricalcitol)</td><td rowspan=1 colspan=1>0.002</td></tr><tr><td rowspan=1 colspan=1>Rocaltrol (calcitriol)</td><td rowspan=1 colspan=1>0.0017</td></tr></table>

Cross reactivity:

A cross-reactivity study was conducted according to CLSI-EP7-A2 to evaluate the potential cross-reactivity of the assay with other vitamin D metabolites. The potential cross-reactants were added at defined concentrations to native human sera with approximate 25-hydroxyvitamin D concentrations of 25, 40, and $6 0 ~ \mathrm { n g / m L }$ , and analyzed with the Elecsys Vitamin D total II assay on the cobas e 411analyzer. Results from the spiked serum samples were matched against the unspiked references and the $\%$ cross-reactivity was calculated using the equation below.

<table><tr><td rowspan=1 colspan=1>Cross-reactant</td><td rowspan=1 colspan=1>Concentrationof spikedcrossreactants(ng/mL)</td><td rowspan=1 colspan=1>Non -NormalizedMean CrossReactivity %</td><td rowspan=1 colspan=1>NormalizedMean CrossReactivity %</td></tr><tr><td rowspan=1 colspan=1>25-hydroxy VitaminD2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>84.0</td><td rowspan=1 colspan=1>93.7</td></tr><tr><td rowspan=1 colspan=1>25-hydroxy VitaminD3</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>89.8</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>24,25-dihydroxyVitamin D3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>13.7</td></tr><tr><td rowspan=1 colspan=1>3-epi 25-hydroxyVitamin D3</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>101.5</td><td rowspan=1 colspan=1>112.8</td></tr><tr><td rowspan=1 colspan=1>3-epi 25-hydroxyVitamin D2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>82.3</td><td rowspan=1 colspan=1>91.4</td></tr><tr><td rowspan=1 colspan=1>1,25-dihydroxyVitamin D3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Not detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>1,25-dihydroxyVitamin D2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Not detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>VitaminD3(Cholecalciferol)</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>VitaminD2(Ergocalciferol)</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.3</td></tr></table>

To reflect the endogenous situation and binding behavior of the metabolite without spiking effect and to avoid potentially underreporting the cross-reactivity to 25- hydroxy Vitamin D2, the observed $\%$ cross-reactivities shown above were normalized to 25-hydroxyvitamin D3 by dividing the respective observed $\%$ crossreactivity by the $\%$ cross-reactivity of 25-hydroxyvitamin D3. The table above shows the mean $\%$ cross-reactivity for both normalized and non-normalized samples.

# High Dose Hook Effect:

The high-dose hook effect of the Elecsys Vitamin D total $\mathrm { I I }$ assay was assessed on the cobas e 411 analyzer. One human serum sample was spiked with analyte to achieve a high 25-OH Vitamin D concentration of approximatly1 $0 { , } 0 0 0 ~ \mathrm { n g / m L }$ . A dilution series was performed using a low level analyte (Vitamin D depleted) serum. The study results show that no hook effect was observed up to $1 0 { , } 0 0 0 \ \mathrm { n g / m L }$ for Elecsys Vitamin D total II.

f. Assay cut-off:

Not applicable

2. Comparison studies:

# a. Method Comparison to Reference Method:

A method comparison study against the ID-LC-MS/MS 25(OH)D Reference Measurement Procedure (RMP) was the basis of the substantial equivalence determination for this submission. A method comparison study to compare the candidate device Elcsys Vitamin D total II with Reference method ID-LC-MS/MS method using a total of 111 native single donor patient serum samples (provided by the Vitamin D Standardization and Certification Program with assigned values by the RMP at CDC, independent from the samples used for standardization) were measured in singleton on the cobas e 411 analyzer. The 25-hydroxyvitamin D values ranged between 5.64 and $9 2 . 8 ~ \mathrm { n g / m L }$ as measured by the Reference Method, LC-MS/MS. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Deming regression results</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.954</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.707</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.982</td></tr><tr><td rowspan=1 colspan=1>Range(ng/mL)</td><td rowspan=1 colspan=1>5.64-92.8</td></tr></table>

# b. Method comparison with predicate device:

A method comparison was performed using the candidate Elecsys Vitamin D total II assay and the predicate Elecsys Vitamin D Assay to assess the bias between the two assays. A total of 105 single native donors serum samples were measured in singleton on the cobas e 411 analyzer in one run covering the entire measuring range of the predicate device. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Deming regression results</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.849</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>0.983</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.955</td></tr><tr><td rowspan=1 colspan=1>Range(ng/mL)</td><td rowspan=1 colspan=1>6.1-56</td></tr></table>

# c. Matrix comparison:

The effect on quantitation of 25-OH Vitamin D with the Elecsys Vitamin D total II assay in the presence of different anticoagulants was determined by comparing values obtained from samples (single donors - native, diluted as well as spiked) drawn into serum, Li-Heparin, K2-EDTA, K3-EDTA plasma primary tubes, and Plasma Gel Separation Tubes (Li-Heparin). A minimum of 45 serum/plasma pairs per sample material were tested in singleton with one reagent lot on one cobas e 411 immunoassay analyzer. The linear regression equations from the comparisons are

given below:

Serum/Li-Heparin Plasma Comparison:   
$\mathrm { y } = 0 . 9 8 4 \mathrm { x } - 0 . 0 . 1 0 , \mathrm { r } = 0 . 9 9 7$   
Serum/K2- EDTA Plasma Comparison:   
$y = 0 . 9 8 1 \mathrm { x } - 0 . 3 4 1 , \mathrm { r } = 0 . 9 9 8$   
Serum/K3- EDTA Plasma Comparison:   
$\scriptstyle \mathrm { y = 0 . 9 9 2 x - 1 . 2 5 , r = 0 . 9 9 8 }$   
Serum/Li-Heparin Plasma Gel Separation Tubes Comparison:   
$\mathrm { y } = 0 . 9 7 4 \mathrm { x } + 0 . 7 3 5 , \mathrm { r } = 0 . 9 9 9$

The data support the package insert claim that serum, Li-Heparin, K2-EDTA and K3- EDTA-plasma as well as Li-Heparin Plasma Gel Separation Tubes are acceptable sample types for use with Elecsys Vitamin D total II.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The reference range study was conducted with reference to the CLSI C28-A3 guideline. Total of 421 serum samples from $50 \%$ males and $50 \%$ females, with $30 \%$ dark skin tone were collected from apparently healthy adults, from 21 to 88 years old. The samples were collected from three regionally diverse U.S regions during the summer and winter seasons (approximately $50 \%$ summer and $50 \%$ winter time) to represent a broad spectrum of UV light exposure in the intended use population. The samples were assayed on the cobas e 411 immunoassay analyzer.

The Reference Interval for the total population of the study for the Elecsys Vitamin D total II assay was calculated using the $9 5 \%$ Reference Interval $( 2 . 5 ^ { \mathrm { t h } }$ to $9 \bar { 7 } . 5 ^ { \mathrm { t h } }$ percentile).

Normal Adults: $7 . 6 1 - 5 5 . 5 \mathrm { n g / m L }$ $( \mathrm { n } { = } 4 2 1 $ ).

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.